Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 3
2010 5
2011 3
2012 1
2013 5
2014 7
2015 5
2016 2
2017 4
2018 7
2019 12
2020 19
2021 15
2022 14
2023 18
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Results by year

Filters applied: . Clear all
Page 1
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
Layman RM, Han HS, Rugo HS, Stringer-Reasor EM, Specht JM, Dees EC, Kabos P, Suzuki S, Mutka SC, Sullivan BF, Gorbatchevsky I, Wesolowski R. Layman RM, et al. Among authors: wesolowski r. Lancet Oncol. 2024 Apr;25(4):474-487. doi: 10.1016/S1470-2045(24)00034-2. Lancet Oncol. 2024. PMID: 38547892 Clinical Trial.
Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.
Williams NO, Quiroga D, Johnson C, Brufsky A, Chambers M, Bhattacharya S, Patterson M, Sardesai SD, Stover D, Lustberg M, Noonan AM, Cherian M, Bystry DM, Hill KL, Chen M, Phelps MA, Grever M, Stephens JA, Ramaswamy B, Carson WE 3rd, Wesolowski R. Williams NO, et al. Among authors: wesolowski r. Ther Adv Med Oncol. 2023 Dec 25;15:17588359231217976. doi: 10.1177/17588359231217976. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 38152697 Free PMC article.
PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study.
Ferrarotto R, Swiecicki PL, Zandberg DP, Baiocchi RA, Wesolowski R, Rodriguez CP, McKean M, Kang H, Monga V, Nath R, Palmisiano N, Babbar N, Sun W, Hanna GJ. Ferrarotto R, et al. Among authors: wesolowski r. Oral Oncol. 2024 Feb;149:106634. doi: 10.1016/j.oraloncology.2023.106634. Epub 2023 Dec 20. Oral Oncol. 2024. PMID: 38118249 Free article. Clinical Trial.
Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase.
Savardekar H, Allen C, Jeon H, Li J, Quiroga D, Schwarz E, Wu RC, Zelinskas S, Lapurga G, Abreo A, Stiff A, Shaffer J, Blaser BW, Old M, Wesolowski R, Xin G, Kendra KL, Chung D, Carson WE 3rd. Savardekar H, et al. Among authors: wesolowski r. Mol Cancer Res. 2024 Mar 1;22(3):308-321. doi: 10.1158/1541-7786.MCR-22-0572. Mol Cancer Res. 2024. PMID: 38015751
Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients.
Minta A, Rose L, Park C, Ramaswamy B, Stover D, Gatti-Mays M, Cherian M, Williams N, Sudheendra P, Wesolowski R, Sardesai S, Lustberg M, Loprinzi CL, Ruddy KJ, Cathcart-Rake E, Trovato S, Dulmage B. Minta A, et al. Among authors: wesolowski r. Support Care Cancer. 2023 Nov 22;31(12):717. doi: 10.1007/s00520-023-08160-0. Support Care Cancer. 2023. PMID: 37991653
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors.
Leidner R, Conlon K, McNeel DG, Wang-Gillam A, Gupta S, Wesolowski R, Chaudhari M, Hassounah N, Lee JB, Ho Lee L, O'Keeffe JA, Lewis N, Pavlakis GN, Thompson JA. Leidner R, et al. Among authors: wesolowski r. J Immunother Cancer. 2023 Oct;11(10):e007725. doi: 10.1136/jitc-2023-007725. J Immunother Cancer. 2023. PMID: 37907221 Free PMC article. Clinical Trial.
Survival outcomes seen with neoadjuvant chemotherapy in the management of locally advanced inflammatory breast cancer (IBC) versus matched controls.
Johnson KC, Grimm M, Sukumar J, Schnell PM, Park KU, Stover DG, Jhawar SR, Gatti-Mays M, Wesolowski R, Williams N, Sardesai S, Pariser A, Sudheendra P, Tozbikian G, Ramaswamy B, Doto D, Cherian MA. Johnson KC, et al. Among authors: wesolowski r. Breast. 2023 Dec;72:103591. doi: 10.1016/j.breast.2023.103591. Epub 2023 Oct 14. Breast. 2023. PMID: 37871527 Free PMC article.
Depression, Inflammation, and Intestinal Permeability: Associations with Subjective and Objective Cognitive Functioning throughout Breast Cancer Survivorship.
Madison AA, Andridge R, Kantaras AH, Renna ME, Bennett JM, Alfano CM, Povoski SP, Agnese DM, Lustberg M, Wesolowski R, Carson WE 3rd, Williams NO, Reinbolt RE, Sardesai SD, Noonan AM, Stover DG, Cherian MA, Malarkey WB, Kiecolt-Glaser JK. Madison AA, et al. Among authors: wesolowski r. Cancers (Basel). 2023 Sep 4;15(17):4414. doi: 10.3390/cancers15174414. Cancers (Basel). 2023. PMID: 37686689 Free PMC article.
Inflamed but not impulsive: Acute inflammatory cytokine response does not impact prepotent response inhibition.
Madison AA, Andridge R, Renna ME, Sheridan JF, Lustberg M, Ramaswamy B, Wesolowski R, Williams NO, Sardesai SD, Noonan AM, Reinbolt RE, Cherian MA, Malarkey WB, Kiecolt-Glaser JK. Madison AA, et al. Among authors: wesolowski r. J Affect Disord. 2023 Dec 1;342:1-9. doi: 10.1016/j.jad.2023.09.008. Epub 2023 Sep 7. J Affect Disord. 2023. PMID: 37683942 Clinical Trial.
109 results